Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Elanco Animal Health (ELAN) Stock Soaring – What's Behind the Surge?

This morning we watched Elanco Animal Health rise 1.5% to a price of $22.58 per share. The Large-Cap Pharmaceutical company is now trading -6.24% below its average target price of $24.08. Analysts have set target prices ranging from $18.0 to $27.0 per share for Elanco Animal Health, and have given the stock an average rating of buy.

Elanco Animal Health has an average level of shares sold short, at 6.1% of its total share float. The stock's short ratio (also called days to cover) is 4.44. The company's insiders own 1.05% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Institutional investors own 116.2% of Elanco Animal Health's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Elanco Animal Health

Date Reported Holder Percentage Shares Value
2025-09-30 Dodge & Cox Inc. 17% 82,759,837 $1,868,717,113
2025-09-30 FMR, LLC 13% 65,357,380 $1,475,769,635
2025-09-30 Primecap Management Company 10% 49,958,156 $1,128,055,158
2025-09-30 Vanguard Group Inc 10% 48,586,708 $1,097,087,862
2025-09-30 Blackrock Inc. 9% 46,178,502 $1,042,710,571
2025-09-30 T. Rowe Price Investment Management, Inc. 6% 31,510,014 $711,496,113
2025-09-30 Dimensional Fund Advisors LP 5% 24,708,676 $557,921,902
2025-09-30 UBS Group AG 3% 16,468,148 $371,850,780
2025-09-30 State Street Corporation 3% 15,245,783 $344,249,778
2025-09-30 Black Creek Investment Management Inc. 3% 12,482,461 $281,853,968
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS